Drug class
Amyloid beta-directed humanised IgG1 monoclonal antibody; anti-amyloid biologic
Mechanism of action
Binds insoluble N-terminally truncated pyroglutamate amyloid beta in amyloid plaques and promotes their clearance through immune-mediated mechanisms. The therapeutic target is amyloid pathology; treatment does not reverse established neuronal loss.
General use cases
- Treatment of Alzheimer disease in adults with mild cognitive impairment or mild dementia stage, with confirmed amyloid pathology, under the US product indication; MRI monitoring and risk-management requirements apply
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
